Skip to main content

Table 3 PI-RADSv2.1 and PI-RADSv2 scores assigned by the three groups of readers

From: Characterization of high-grade prostate cancer at multiparametric MRI: assessment of PI-RADS version 2.1 and version 2 descriptors across 21 readers with varying experience (MULTI study)

   

Benign lesions & ISUP 1 cancers

csPCas

   

Experienced seniors

Less experienced seniors

Juniors

Experienced seniors

Less experienced seniors

Juniors

Predefined lesions (N = 240)

PI-RADSv2.1

1

4 [2–12]

4 [1–5]

8 [2–9]

1 [0–2]

1 [0–1]

1 [0–1]

  

2

49 [20–61]

20 [14–39]

22 [19–52]

5 [3–6]

0 [0–2]

4 [2–9]

  

3

24 [18–29]

15 [12–18]

33 [28–34]

5 [4–7]

4 [3–6]

8 [3–11]

  

4

65 [44–86]

96 [90–111]

73 [56–95]

35 [34–39]

39 [38–41]

35 [34–39]

  

5

11 [8–15]

13 [11–20]

15 [10–24]

32 [28–36]

33 [30–35]

32 [26–35]

 

PI-RADSv2.0

1

3 [1–10]

2 [1–3]

2 [1–7]

1 [0–3]

0 [0–0]

0 [0–1]

  

2

28 [17–41]

23 [12–24]

21 [12–23]

3 [2–5]

1 [0–4]

2 [1–3]

  

3

26 [21–32]

16 [12–18]

38 [29–44]

5 [5–7]

3 [2–4]

10 [3–12]

  

4

87 [49–97]

105 [100–112]

78 [71–97]

38 [34–40]

40 [38–43]

41 [37–42]

  

5

11 [9–15]

13 [11–19]

15 [11–24]

32 [28–36]

34 [31–35]

32 [26–35]

Per-lobe analysis (N = 318)

PI-RADSv2.1

1

71 [7–78]

49 [8–58]

50 [22–57]

4 [0–7]

1 [0–3]

4 [2–6]

  

2

57 [48–60]

49 [21–75]

40 [37–61]

5 [4, 5]

3 [2–7]

4 [2–5]

  

3

33 [22–33]

17 [14–18]

37 [32–47]

5 [3–6]

5 [2–10]

8 [3–10]

  

4

60 [46–88]

99 [89–108]

77 [58–96]

36 [32–39]

37 [37–39]

36 [35–38]

  

5

18 [11–23]

15 [12–23]

19 [15–35]

43 [36–49]

42 [39–44]

43 [35–49]

 

PI-RADSv2.0

1

1 [0–2]

1 [0–2]

1 [0–3]

0 [0–1]

0 [0–0]

0 [0–1]

  

2

107 [77–114]

82 [63–89]

65 [58–83]

6 [5–11]

7 [5–9]

6 [4–8]

  

3

31 [22–39]

15 [11–23]

37 [28–51]

5 [3–6]

3 [2–4]

8 [3–10]

  

4

79 [54–101]

106 [102–112]

81 [72–98]

39 [31–41]

38 [36–41]

38 [36–40]

  

5

18 [11–24]

15 [12–22]

19 [15–35]

43 [36–49]

42 [42–46]

43 [36–49]

  1. Data are presented as median number of lesions/lobes [interquartile range]
  2. N Number of lesions/lobes, csPCas Clinically significant prostate cancers, ISUP International society of urological pathology, PI-RADS prostate imaging-reporting and data system